4-(2-(4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)ethyl)benzoic acid | 1401968-22-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2-(4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)ethyl)benzoic acid
• 英文别名: 4-[2-[4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]ethyl]benzoic acid
• CAS: 1401968-22-6
• 化学式: C₂₄H₃₀N₂O₂
• 分子量: 378.514
• InChiKey: FATVFHQEUQEDLF-XZOQPEGZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  52.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• CYCLOPROPYLAMINES AS LSD1 INHIBITORS
  申请人：GlaxoSmithKline Intellectual Property (No.2) Limited

  公开号：US20140371176A1

  公开（公告）日：2014-12-18

  This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.

  本发明涉及使用环丙胺衍生物来调节，特别是抑制赖氨酸特异性去甲基化酶1（LSD1）的活性。适当地，本发明涉及使用环丙胺衍生物治疗癌症。
• Cyclopropylamines as LSD1 inhibitors
  申请人：GlaxoSmithKline Intellectual Property (No.2) Limited

  公开号：US10064854B2

  公开（公告）日：2018-09-04

  This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.

  本发明涉及使用环丙胺衍生物来调节，特别是抑制赖氨酸特异性去甲基化酶 1（LSD1）的活性。因此，本发明涉及环丙胺在癌症治疗中的应用。
• USE OF A COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH CDK2 INHIBITORS IN THE TREATMENT OF CANCER
  申请人：Rasna Therapeutics Limited

  公开号：US20180311245A1

  公开（公告）日：2018-11-01

  The present disclosure relates to methods of treating cancer and pharmaceutical compositions for use in the treatment of cancer, including LSD1-inhibitor-resistant cancers, comprising administering to a subject an effective amount of a CDK2 inhibitor and an effective amount of a LSD1 inhibitor.
• USE OF A COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER
  申请人：Istituto Europeo di Oncologia S.r.l.

  公开号：US20210100800A1

  公开（公告）日：2021-04-08

  The present disclosure relates to methods of treating cancer and pharmaceutical compositions for use in the treatment of cancer, including LSD1-inhibitor-resistant cancers, comprising administering to a subject an effective amount of a cell cycle inhibitor, such as a CDK4/6 inhibitor or a p21 enhancer, and an effective amount of a LSD1 inhibitor.
• US8853408B2
  申请人：——

  公开号：US8853408B2

  公开（公告）日：2014-10-07